BCV vs. HQL, KTF, MCI, SOR, PPT, MIY, MHN, PMO, WHF, and ASG
Should you be buying Bancroft Fund stock or one of its competitors? The main competitors of Bancroft Fund include Abrdn Life Sciences Investors (HQL), DWS Municipal Income Trust (KTF), Barings Corporate Investors (MCI), Source Capital (SOR), Putnam Premier Income Trust (PPT), BlackRock MuniYield Michigan Quality Fund (MIY), BlackRock MuniHoldings New York Quality Fund (MHN), Putnam Municipal Opportunities Trust (PMO), WhiteHorse Finance (WHF), and Liberty All-Star Growth Fund (ASG). These companies are all part of the "investment offices, not elsewhere classified" industry.
Abrdn Life Sciences Investors (NYSE:HQL) and Bancroft Fund (NYSE:BCV) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.
In the previous week, Abrdn Life Sciences Investors had 2 more articles in the media than Bancroft Fund. MarketBeat recorded 2 mentions for Abrdn Life Sciences Investors and 0 mentions for Bancroft Fund. Bancroft Fund's average media sentiment score of 0.88 beat Abrdn Life Sciences Investors' score of 0.00 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the media.
Abrdn Life Sciences Investors received 95 more outperform votes than Bancroft Fund when rated by MarketBeat users.
32.2% of Abrdn Life Sciences Investors shares are held by institutional investors. Comparatively, 22.4% of Bancroft Fund shares are held by institutional investors. 10.1% of Abrdn Life Sciences Investors shares are held by insiders. Comparatively, 4.1% of Bancroft Fund shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Abrdn Life Sciences Investors has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Bancroft Fund has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.
Abrdn Life Sciences Investors pays an annual dividend of $1.49 per share and has a dividend yield of 11.2%. Bancroft Fund pays an annual dividend of $1.28 per share and has a dividend yield of 8.2%. Bancroft Fund has increased its dividend for 1 consecutive years.
Summary
Abrdn Life Sciences Investors beats Bancroft Fund on 6 of the 8 factors compared between the two stocks.
Get Bancroft Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bancroft Fund Competitors List
Related Companies and Tools
